Current Report Filing (8-k)
February 20 2020 - 5:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2020
Baudax Bio, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
001-39101
|
|
47-4639500
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
490 Lapp Road, Malvern, Pennsylvania
|
|
19355
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484)
395-2470
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Trading
Symbol
|
|
Name of Exchange
on Which Registered
|
Common Stock, par value $0.01
|
|
BXRX
|
|
Nasdaq Capital Market
|
Securities registered pursuant to Section 12(g) of the Act:
None
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 7.01
|
Regulation FD Disclosure.
|
On February 20, 2020, Baudax Bio, Inc. (the Company) updated information reflected in a slide presentation, which representatives of
the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.1, and incorporated herein by reference.
The information disclosed under Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On February 20, 2020, the Company issued a press release announcing that the U.S. Food and Drug Administration has approved the New Drug Application for
ANJESO (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID
analgesics. A copy of the press release is attached hereto as Exhibit 99.2, and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibits are being filed
herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
Baudax Bio, Inc.
|
|
|
By:
|
|
/s/ Gerri A. Henwood
|
Name:
|
|
Gerri A. Henwood
|
Title:
|
|
Chief Executive Officer
|
Date: February 20, 2020
Baudax Bio (NASDAQ:BXRXV)
Historical Stock Chart
From May 2024 to May 2024
Baudax Bio (NASDAQ:BXRXV)
Historical Stock Chart
From May 2023 to May 2024